InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Investor Presentation (May 2023)
23 slides from InMed Pharmaceuticals's investor presentation, May 2023
Slide 1: Corporate Presentation
Corporate Presentation May 2023 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: A Pure-Play Rare Cannabinoid Company
A Pure-Play Rare Cannabinoid Company RARE CANNABINOID EXPERTISE ACROSS SEVERAL AREAS Pharmaceutical R&D Manufacturing Drug Discovery Commercial 3 : INM
Slide 4: Cannabinoid Drug Development Programs
Cannabinoid Drug Development Programs
Slide 5: Pharmaceutical Development of Rare Cannabinoids
Pharmaceutical Development of Rare Cannabinoids HIGHLIGHTS SCREENING PRECLINICAL PH 1 PH 2 PH 3 NATURALLY-OCCURRING CANNABINOIDS INM-755 CBN Phase 2 - enrollment completed Targeting symptomatic relief in itch pain and Epidermolysis bullosa wound healing and chronic inflammation INM-088 CBN Front of
Slide 6: Epidermolysis Bullosa – A Significant Unmet Medical Need
Epidermolysis Bullosa – A significant Unmet Medical Need A RARE DISEASE WITH NO APPROVED THERAPIES Unmet medical need What is EB? A rare and debilitating connective tissue disorder with no cure or approved treatments. Current treatments offer A rare genetic skin disease characterized some symptom re
Slide 7: Phase 2: INM-755 Cannabinol (CBN) Cream
Phase 2: INM-755 Cannabinol (CBN) Cream FIRST AND ONLY CBN FORMULATION TO ADVANCE TO A PHASE 2 CLINICAL TRIAL Primary Endpoint • Preliminary efficacy in treating symptoms and healing Milestones wounds over a 28-day period Enrollment completed Trial Design March 2023. • Within-patient randomized, dou
Slide 8: Glaucoma – Leading Cause of Blindness for Age 60+
Glaucoma – Leading Cause of Blindness for Age 60+ CURRENT MEDICATIONS WORK TO REDUCE INTRAOCULAR PRESSURE Unmet medical need Glaucoma market Current treatments do not proactively protect the eye or reverse Second leading cause of blindness the progression of glaucoma and only slow the progression of
Slide 9: INM-088: Potential Roles for CBN in Glaucoma
INM-088: Potential Roles for CBN in Glaucoma CANNABINOL DEMONSTRATES REDUCTION OF IOP AND NEUROPROTECTIVE EFFECTS Front of eye Back of eye IOP reduction Neuroprotection Target Effects of CBN Retina • Direct neuroprotection for the retina and optic nerve, independent of intraocular Pressure pressure
Slide 10: Neurodegenerative Diseases – A Gap in Treatment
Neurodegenerative Diseases – A Gap in Treatment CANNABINOIDS SHOWN TO INHIBIT NEURODEGENERATIVE DISEASE PROGRESSION IN PRECLINICAL MODELS Unmet medical need Medications to treat Alzheimer's may slow the rate of cognitive Milestones decline but none have been shown to halt nor reverse its PCT patent
Slide 11: Neurodegenerative Diseases – Market Assessment
Neurodegenerative Diseases – Market Assessment ALZHEIMER’S PARKINSON’S HUNTINGTON’S $13B $9.4B 20% MARKET BY 2031 MARKET BY 2030 CAGR BY 2032 • Alzheimer's treatment market is estimated • Global Parkinson's disease drugs market is • Global Huntington’s Disease treatment at $6.1B in 2021 with a CAGR
Slide 12: Cannabinoids Can Act on Receptors Expressed in the Brain
Cannabinoids Can Act on Receptors Expressed in the Brain CANNABINOIDS ARE HIGHLY LIPOPHILIC Examples of receptors expressed in the brain CB1 Receptors concentrated in the brain and central nervous system but are also present in some nerves and organs GPR6 Receptors mainly expressed in the brain, par
Slide 13: Potential to Enhance Neuronal Function
Potential to enhance neuronal function SELECTED CANNABINOID ANALOGS DEMONSTRATES NEUROPROTECTIVE EFFECTS Cannabinoid analogs increased neurite outgrowth The selected cannabinoid analogs demonstrated neuroprotective effects and enhanced neuronal Differentiated Differentiated neuronal cells function n
Slide 14: A Diverse Patent Portfolio
A Diverse Patent Portfolio 13 PATENT FAMILIES – NCEs/Formulations, Manufacturing Methods, Methods of Use, NCEs Manufacturing Methods of use 2 patent families filed 7 patent families filed 4 patent families filed • 21 international pending • 2 granted • 2 granted • 29 international pending • 22 inter
Slide 15: Rare Cannabinoid Manufacturing
Rare Cannabinoid Manufacturing
Slide 16: Unparalleled Cannabinoid Manufacturing Expertise
Unparalleled Cannabinoid Manufacturing Expertise NO OTHER COMPANY HAS THE SAME BREADTH AND DEPTH IN CANNABINOID MANUFACTURING Manufacturing Approaches Biosynthesis Chemical Synthesis • Able to select the most effective manufacturing method depending on the target cannabinoid • Ability to scale to me
Slide 17: BayMedica – Wholesale Rare Cannabinoids for the H&W Market
BayMedica -Wholesale Rare Cannabinoids for the H&W Market HIGH PURITY, CONSISTENT & BIOIDENTICAL TO NATURE CBC CBDV THCV CBT Cannabichromene Cannabidivarin Tetrahydrocannabivarin Cannabicitran CONSISTENCY C O S T- E F F E C T I V E N E S S High quality, bioidentical rare cannabinoids with exceptiona
Slide 18: BayMedica – Revenue Trending Positively
BayMedica – Revenue Trending Positively INCREASED DEMAND FOR BAYMEDICA’S BIOIDENTICAL RARE CANNABINOIDS Fiscal 2023 Revenue Growth US$ 1200000 • Surpassed $1M sales in Q3 2023 $1.03M 1000000 +120% • Last 2 periods : 46% and 120% quarter over quarter growth 800000 • Increased adoption of rare cannabi
Slide 19: Corporate
Corporate
Slide 20: Financial Snapshot
Financial Snapshot As of 2023-05-12 Cash and Short-term Investments (As of March 31, 2023) $9.6 M Shares I/O 3.33 M Options 0.11 M Warrants and Preferred Investment Options 3.53 M Fully Diluted Shares 6.97 M Close US$1.15 52-week High US$28.50 52-week Low US$0.92 Avg. Daily Volume (Trailing 50 Days)
Slide 21: Bringing Together a Depth of Cannabinoid Expertise
Bringing Together a Depth of Cannabinoid Expertise EXTENSIVE EXPERIENCE IN PHARMA R&D, CANNABINOID/API MANUFACTURING, CLINICAL AND REGULATORY Eric A. Adams, MIBS Michael Woudenberg, PEng Alexandra Mancini, MSc Eric Hsu, PhD Sarah Li, CPA, CGA Chief Executive Officer Chief Operating Officer SVP, Clin
Slide 22: Calendar 2023 – Key Value Drivers
Calendar 2023 – Key Value Drivers • EB Phase 2 clinical data read out in 3Q 2023 • Advance glaucoma program towards human clinical trials • Initiate in vivo studies in neurodegenerative disease • Target proprietary cannabinoid analogs for pharma R&D • Continue to support revenue growth in BayMedica
Slide 23: Thank you!
UNLOCKING THE POTENTIAL OF CANNABINOID MEDICINES Thank you! Colin Clancy Vice President, Investor Relations & Corporate Communications [email protected] +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (May 2023) on 6ix